Identification
- Brand Names
- Abelcet
- Generic Name
- DL-dimyristoylphosphatidylglycerol
- DrugBank Accession Number
- DB11284
- Background
DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for DL-dimyristoylphosphatidylglycerol (DB11284)
- Weight
- Average: 666.874
Monoisotopic: 666.447185355 - Chemical Formula
- C34H67O10P
- Synonyms
- Dimyristoylphosphatidylglycerol
- DMPG
Pharmacology
- Indication
DL-dimyristoylphosphatidylglycerol is not an considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indications.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
DL-dimyristoylphosphatidylglycerol is a water soluble phospholipid used to solubilize drugs for injection 1.
- Mechanism of action
As a phospholipid, DL-dimyristoylphosphatidylglycerol can form a micelle with a hydrophobic core to contain lipophilic drugs while maintaining a hyrophilic outer portion to allow increased solubility of the drug in the aqueous environment of the blood or gastrointestinal tract 1.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Abelcet DL-dimyristoylphosphatidylglycerol (1.5 mg/1mL) + Amphotericin B (5 mg/1mL) + DL-dimyristoylphosphatidylcholine (3.4 mg/1mL) Injection Intravenous Leadiant Biosciences, Inc. 2010-10-18 Not applicable US 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phosphatidylglycerols. These are glycerophosphoglycerols in which two fatty acids are bonded to the 1-glycerol moiety through ester linkages. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Glycerophospholipids
- Sub Class
- Glycerophosphoglycerols
- Direct Parent
- Phosphatidylglycerols
- Alternative Parents
- Fatty acid esters / Dialkyl phosphates / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / 1,2-diols / Primary alcohols / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- 1,2-diacylglycerophosphoglycerol / 1,2-diol / Alcohol / Aliphatic acyclic compound / Alkyl phosphate / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl phosphate / Dicarboxylic acid or derivatives
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- phosphatidylglycerol (CHEBI:60723)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- BI71WT9P3R
- CAS number
- 61361-72-6
- InChI Key
- BPHQZTVXXXJVHI-UHFFFAOYSA-N
- InChI
- InChI=1S/C34H67O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-33(37)41-29-32(30-43-45(39,40)42-28-31(36)27-35)44-34(38)26-24-22-20-18-16-14-12-10-8-6-4-2/h31-32,35-36H,3-30H2,1-2H3,(H,39,40)
- IUPAC Name
- [2,3-bis(tetradecanoyloxy)propoxy](2,3-dihydroxypropoxy)phosphinic acid
- SMILES
- CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC
References
- General References
- Strickley RG: Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004 Feb;21(2):201-30. [Article]
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intravenous - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6406713 No 2002-06-18 2019-06-18 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000281 mg/mL ALOGPS logP 6.79 ALOGPS logP 9.16 Chemaxon logS -6.4 ALOGPS pKa (Strongest Acidic) 1.89 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 148.82 Å2 Chemaxon Rotatable Bond Count 36 Chemaxon Refractivity 176.9 m3·mol-1 Chemaxon Polarizability 80.16 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 260.16956 predictedDeepCCS 1.0 (2019) [M+H]+ 262.52756 predictedDeepCCS 1.0 (2019) [M+Na]+ 270.33197 predictedDeepCCS 1.0 (2019)
Drug created at December 03, 2015 16:52 / Updated at September 28, 2021 21:54